How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Parkinson's Disease Treatments Market
- By Treatment Type: Levodopa-based therapies, Dopamine agonists, MAO-B inhibitors, COMT inhibitors, Anticholinergic agents, Amantadine
- By Drug Delivery Method: Oral tablets/capsules, Transdermal patches, Injectable formulations, Inhalation therapies, Infusion pumps
- By Disease Stage: Early-stage Parkinson's, Mid-stage Parkinson's, Advanced-stage Parkinson's
- By Therapeutic Approach: Symptomatic treatment, Neuroprotective treatment, Adjunctive therapy
- By Patient Demographics: Elderly patients, Young-onset Parkinson's patients, Patients with motor fluctuations
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Levodopa-based therapies leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.186 →
Full report · locked preview
Everything inside the Parkinson's Disease Treatments Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 6
Drug Delivery Method 5
Disease Stage 3
Therapeutic Approach 3
Patient Demographics 3
Companies profiled
AbbVie Inc.
Teva Pharmaceutical Industries Ltd.
Novartis AG
UCB S.A.
Sunovion Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.
Lundbeck A/S
Ipsen S.A.
Mitsubishi Tanabe Pharma Corporation
BIAL - Portela & Cª
S.A.
Amneal Pharmaceuticals LLC
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →UCB S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sunovion Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Acadia Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Lundbeck A/S
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Ipsen S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Mitsubishi Tanabe Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →BIAL - Portela & Cª
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Amneal Pharmaceuticals LLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Zambon Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Curemark LLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Axovant Sciences Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Intec Pharma Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →
Global · 2025–2033
$3,565M by 2033 · 6.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Levodopa-based therapies35.7
- Dopamine agonists12.6
- MAO-B inhibitors12.8
- COMT inhibitors12.9
- Anticholinergic agents13.2
- Amantadine12.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$720.4M → $1,175M · 6.3%
Europe$502.1M → $888.0M · 7.4%
Asia Pacific$458.5M → $687.3M · 5.2%
Latin America$283.8M → $415.1M · 4.9%
Middle East and Africa$218.3M → $334.5M · 5.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.282026
6.292027
6.312028
6.312029
6.322030
6.342031
6.342032
6.362033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- AbbVie Inc.17.1
- Teva Pharmaceutical Industries Ltd.17.5
- Novartis AG9.9
- UCB S.A.10.2
- Sunovion Pharmaceuticals Inc.9.2
- Acadia Pharmaceuticals Inc.8.0
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type16.1%
Drug Delivery Method19.6%
Disease Stage16.9%
Therapeutic Approach17.5%
Patient Demographics29.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.6
- Europe25.4
- Asia Pacific19.6
- Latin America11.9
- Middle East and Africa9.6
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | 91 | 74 | 95 | 92 | 76 | 80 | 85 |
| Teva Pharmaceutical Industries Ltd. | 78 | 82 | 90 | 93 | 90 | 77 | 85 |
| Novartis AG | 80 | 65 | 73 | 71 | 85 | 84 | 76 |
| UCB S.A. | 64 | 60 | 63 | 67 | 70 | 63 | 65 |
| Sunovion Pharmaceuticals Inc. | 72 | 72 | 56 | 66 | 68 | 57 | 65 |
| Acadia Pharmaceuticals Inc. | 56 | 58 | 61 | 54 | 60 | 68 | 60 |
| Lundbeck A/S | 60 | 43 | 49 | 54 | 53 | 51 | 52 |
| Ipsen S.A. | 38 | 53 | 60 | 58 | 52 | 59 | 53 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| AbbVie Inc. | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Teva Pharmaceutical Industries Ltd. | ✓ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Novartis AG | ✓ | − | ✓ | ◐ | ✓ | ◐ |
| UCB S.A. | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Sunovion Pharmaceuticals Inc. | ◐ | ◐ | ◐ | ✓ | ◐ | − |
| Acadia Pharmaceuticals Inc. | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Lundbeck A/S | ◐ | ◐ | − | ◐ | − | ◐ |
| Ipsen S.A. | − | − | − | ◐ | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1AbbVie Inc.85
2Teva Pharmaceutical Industries Ltd.85
3Novartis AG76
4UCB S.A.65
5Sunovion Pharmaceuticals Inc.65
6Acadia Pharmaceuticals Inc.60
7Ipsen S.A.53
8Lundbeck A/S52
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
AbbVie Inc.Teva Pharmaceutical Industries Ltd.
Challenger1
Strong scale, closing on the leaders.
Novartis AG
Contender3
Focused players with pockets of strength.
UCB S.A.Sunovion Pharmaceuticals Inc.Acadia Pharmaceuticals Inc.
Niche2
Specialists in a single segment or region.
Lundbeck A/SIpsen S.A.
Go-to-market strategy
Land Treatment Type in North America, then scale across Parkinson's Disease Treatments Market — a $276M beachhead inside a $4.22B market.
Beachhead (SOM)$276Mobtainable near-term
Serviceable (SAM)$1.60Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Levodopa-based therapies
Best fit — highest urgency & budget in Treatment Type.
Economic buyer78 fit
Dopamine agonists
Strong fit — clear ROI and a fast path to value.
End user68 fit
MAO-B inhibitors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Delivery Method & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Disease Stage
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel32%
Digital / self-serve19%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Parkinson's Disease Treatments Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified24%
Evaluation12%
Closed-won8%
$15.9KCAC
$68KLTV
4.3:1LTV : CAC
< 4 moCAC payback
Investment thesis
Parkinson's Disease Treatments Market is a resilient opportunity — $648M by 2033, compounding at 4.4%.
TAM · 2025$459Mtoday
TAM · 2033$648Mforecast
CAGR4.4%2027–2033
Cumulative$4.94Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$648MTotal addressable market
SAM$248MServiceable available market
SOM$40MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.4% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$648MLarge & growingTAM by 2033 at 4.4% CAGR
$248MServiceable nowreachable with today’s model
$40MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$505MBear2.9% CAGR
$648MBase4.4% CAGR
$829MBull5.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Delivery Method optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Parkinson's Disease Treatments Market — a $10.7B market by 2033. Plan: grow share from 7.6% to 16.9%.
Market size · 2033$10.7Btotal addressable
Market CAGR11.5%2027–2033
Target share16.9%from 7.6% today
Revenue ambition$1.81Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.6% | 16.9% | On track |
| Revenue | $745M | $1.81B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 35.4% | 41.7% | At risk |
| Customer retention | 86.7% | 92.6% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Delivery Method capability
A defensible second engine — invest in Drug Delivery Method to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Delivery Method
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $269M capacity & capability investment
- Greenlight bolt-on M&A in Drug Delivery Method
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentBehind
Sales deck · value proposition
Win the Parkinson's Disease Treatments Market conversation — a $4.69B market you can size, segment and defend in minutes.
Market size · 2033$4.69Btotal opportunity
Growth8.9%CAGR to 2033
Addressable buyers951+accounts in scope
Typical ROI6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6×return on cost, year one
< 3 mopayback period
$43K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
AbbVie Inc.Teva Pharmaceutical Industries Ltd.Novartis AGUCB S.A.Sunovion Pharmaceuticals Inc.Acadia Pharmaceuticals Inc.Lundbeck A/SIpsen S.A.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Parkinson's Disease Treatments Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Parkinson's Disease Treatments Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Nasal Polyposis Drug Market
Market size, share, segmentation and regional forecast.
$7.6B by 2031 · 3.71% CAGR
View reportHepatic Encephalopathy Drug Market
Market size, share, segmentation and regional forecast.
$3.6B by 2033 · 10.43% CAGR
View reportUnilateral Cochlear Implants Market
Market size, share, segmentation and regional forecast.
$12.9B by 2031 · 4.05% CAGR
View reportInfectious Disease Diagnostics Market
Market size, share, segmentation and regional forecast.
$7.9B by 2031 · 6.12% CAGR
View reportPoliomyelitis Vaccine Market
Market size, share, segmentation and regional forecast.
$3.9B by 2032 · 3.80% CAGR
View reportSeasonal Influenza Vaccines Market
Market size, share, segmentation and regional forecast.
$926M by 2031 · 7.06% CAGR
View reportOncology Drug Market
Market size, share, segmentation and regional forecast.
$13.2B by 2033 · 10.68% CAGR
View reportBiologic Therapeutics Drugs Market
Market size, share, segmentation and regional forecast.
$1.1B by 2033 · 4.44% CAGR
View reportSuperdisintegrants Market
Market size, share, segmentation and regional forecast.
$11.2B by 2033 · 6.23% CAGR
View reportBeta Blocker Market
Market size, share, segmentation and regional forecast.
$11.4B by 2033 · 4.09% CAGR
View reportHuman Vaccines Market
Market size, share, segmentation and regional forecast.
$4.5B by 2031 · 3.97% CAGR
View reportContraceptive Devices Market
Market size, share, segmentation and regional forecast.
$13.4B by 2033 · 3.39% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.